15 results
8-K
EX-99.1
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
) charges associated with the wind-down of contracts associated with our clinical trial program, (iii) severance expenses incurred which were directly
8-K
EX-99.1
MDXG
Mimedx Group Inc
28 Feb 24
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
4:22pm
Medicine segment. This reflects (i) write-downs of clinical trial assets, (ii) charges associated with the wind-down of contracts associated with our
8-K
EX-99.1
MDXG
Mimedx Group Inc
30 Oct 23
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
4:05pm
channel, and a contribution associated with the wind-down of a product line related to the end of a contract.
Gross Profit and Margin
Gross profit … . This reflects (i) write-downs of clinical trial assets, (ii) charges associated with the wind-down of contracts associated with our clinical trial program
8-K
EX-99.1
fjn0vhsz6b51m
1 Aug 23
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
4:03pm
8-K
EX-99.1
isxjj6ahckrs2r1bk
20 Jun 23
Departure of Directors or Certain Officers
4:03pm
DEFC14A
jczko792gctdcllk2lyd
28 May 19
Proxy in contested solicitation
5:21pm
PRRN14A
lnub 42ebtqiqv2f
20 May 19
Revised preliminary proxy statement filed by non-management
5:16pm
PREC14A
jfvjf5w in55dbuwwk
10 May 19
Preliminary proxy with contested solicitation
4:38pm
8-K
EX-99.1
hxfp0fdmalr
17 Jul 17
MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range
12:00am
- Prev
- 1
- Next